A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital

Atrial Fibrillation Clinical Trial

Official title:

A Prospective Randomized Study of Different Digoxin Treatment Regimens in Egyptian Hospital

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02489786
• Other study ID #: CL (312)
• Status: Completed
• Phase: Phase 4
• First received: July 1, 2015
• Last updated: July 3, 2015
• Start date: October 2012
• Est. completion date: October 2014

Study information

• Verified date: July 2015
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Egypt: Ministry of Higher Education
• Study type: Interventional

Clinical Trial Summary

Digoxin is the primary cardiac glycoside in clinical use. Because of the narrow therapeutic index and risk of toxicity, therapeutic drug monitoring is highly recommended. In Egypt, most cardiologists give digoxin holiday for both atrial fibrillation and heart failure, it is not clear if the interrupted digoxin regimens are effective since serum digoxin concentrations might fall below the therapeutic range.

Objective: To evaluate and compare the digoxin serum concentration and patient's quality of life in the continuous versus interrupted digoxin dosing regimens.

Description:

Digoxin is a cardiac glycoside prescribed in heart failure and certain supraventricular tachyarrhythmias. It exerts a positive inotropic, neurohormonal, and electro physiologic actions on the heart . For heart failure patients, the targeted steady state serum digoxin level is between 0.5 and 0.8 ng/ml . Ventricular rate control in atrial fibrillation patients will usually require higher digoxin steady state serum concentrations . However, serum digoxin level higher than 2 ng/ml is associated with increased incidence of adverse drug reactions and should be avoided . Because of inter and intra-patient variability, narrow therapeutic index, and risk of toxicity, digoxin doses are calculated based on the patient weight, renal status, indications and drug interactions. Due to substantial overlap between therapeutic and toxic levels of digoxin, therapeutic drug monitoring is a must especially in patients with deteriorating renal function and electrolyte disturbance. In Egypt, most cardiologists give a digoxin holiday for patients with atrial fibrillation and /or heart failure where patients skip the drug doses on Thursday and Friday or Friday only every week to avoid possible drug accumulation and toxicity. It is not clear if these interrupted digoxin regimens really offer safer alternative over the continuous dosing regimens without compromising the effectiveness. It is anticipated that plasma digoxin levels may fall below the therapeutic range during the holiday which may affect patient clinical status and quality of life.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: October 2014
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with atrial fibrillation (AF)

• with or without congestive heart failure (CHF)

• taking digoxin tablets with or without holiday regimens

Exclusion Criteria:

• taking the following drugs concurrently: amiodarone, verapamil, quinidine and propafenone.

• diagnosed with thyroid disorders (hyperthyroidism & hypothyroidism).

• diagnosed with renal failure

• pregnant

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Drug:
• patients take 0.25 mg of digoxin daily except friday

• patients take 0.25 mg of digoxin daily except thursday and friday

• patients take 0.125 mg of digoxin daily

• digoxin dose is calculated using Jusko-Koup method and given daily

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	measuring digoxin trough steady state plasma concentrations for the interrupted and continuous treatment regimens		1 month	No
Secondary	evaluating patients quality of life using quality of life questionnaire for atrial fibrillation patients		1 month	No
Secondary	evaluating signs and symptoms of digoxin side effects and toxicity by using specific structured questions		1 month	No